Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation

Human Reproduction

Volumn 26, Issue 2, 2011, Pages 423-430

  Mumford, Sunni L ^a,b   Schisterman, Enrique F ^a   Siega Riz, Anna Maria ^b,c   Gaskins, Audrey J ^a   Steiner, Anne Z ^d   Daniels, Julie L ^b   Olshan, Andrew F ^b   Hediger, Mary L ^a   Hovey, Kathleen ^e   Wactawski Wende, Jean ^e   Trevisan, Maurizio ^f   Bloom, Michael S ^g  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b The University of North Carolina at Chapel Hill   (United States)

^c University of North Carolina at Chapel Hill   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF NEVADA   (United States)

^g STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

anovulation; endocrine disturbances; lipoproteins; menstrual cycle

Indexed keywords

CHOLESTEROL; FOLLITROPIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL;

ACNE; ADULT; ANOVULATION; ARTICLE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION; METABOLIC DISORDER; OVARY POLYCYSTIC DISEASE; PROSPECTIVE STUDY; SELF CONCEPT;

EID: 79251502316     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/deq322     Document Type: Article

References (39)

1. Abdulla U, Diver MJ, Hipkin LJ, Davis JC. Plasma progesterone levels as an index of ovulation. Br J Obstet Gynaecol 1983;90:543-548.
2. Akram T, Hasan S, Imran M, Karim A, Arslan M. Association of polycystic ovary syndrome with cardiovascular risk factors. Gynecol Endocrinol 2010;26:47-53.
3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-488.
4. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995;10:2107-2111.
5. Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007; 92:456-461.
6. Barbieri RL. Female infertility. In: Strauss JF, Barbieri RL (eds). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th edn. Philadelpha, PA: Elsevier, 2004, 633-668.
7. Browne RW, Bloom MS, Schisterman EF, Hovey K, Trevisan M, Wu C, Liu A, Wactawski-Wende J. Analytical and biological variation of biomarkers of oxidative stress during the menstrual cycle. Biomarkers 2008;13:160-183.
8. Chatterton RT Jr, Mateo ET, Hou N, Rademaker AW, Acharya S, Jordan VC, Morrow M. Characteristics of salivary profiles of oestradiol and progesterone in premenopausal women. J Endocrinol 2005;186:77-84.
9. Cole SR, Hernan MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol 2008;168:656-664.
10. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, Pratt M, Ekelund U, Yngve A, Sallis JF et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003;35:1381-1395.
11. De Souza MJ, Miller BE, Loucks AB, Luciano AA, Pescatello LS, Campbell CG, Lasley BL. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in follicle-stimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 1998;83:4220-4232.
12. Diggle P, Heagerty P, Liang K-Y, Zeger SL. Analysis of Longitudinal Data, 2nd edn. New York, NY: Oxford University Press, 2002.
13. Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006; 85:996-1001.
14. Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S13-S14.
15. Essah PA, Wickham EP, Nestler JE. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:205-225.
16. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-1447.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
18. Gaskins AJ, Mumford SL, Zhang C, Wactawski-Wende J, Hovey KM, Whitcomb BW, Howards PP, Perkins NJ, Yeung E, Schisterman EF et al. Effect of daily fiber intake on reproductive function: the BioCycle Study. Am J Clin Nutr 2009;90:1061-1069.
19. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 2002;17:2495-2499.
20. Howards PP, Schisterman EF, Wactawski-Wende J, Reschke JE, Frazer AA, Hovey KM. Timing clinic visits to phases of the menstrual cycle by using a fertility monitor: the BioCycle Study. Am J Epidemiol 2009; 169:105-112.
21. Hull MG, Glazener CM, Kelly NJ, Conway DI, Foster PA, Hinton RA, Coulson C, Lambert PA, Watt EM, Desai KM. Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 1985;291:1693-1697.
22. Kodaman PH, Duleba AJ. Statins in the treatment of polycystic ovary syndrome. Semin Reprod Med 2008;26:127-138.
23. Lohman TG, Roche AF, Martorell R. Anthropometric Standardization Reference Manual. Champaign, IL: Human Kinetics Books, 1988.
24. Macut D, Panidis D, Glisic B, Spanos N, Petakov M, Bjekic J, Stanojlovic O, Rousso D, Kourtis A, Bozic I et al. Lipid and lipoprotein profile in women with polycystic ovary syndrome. Can J Physiol Pharmacol 2008; 86:199-204.
25. Malcolm CE, Cumming DC. Does anovulation exist in eumenorrheic women? Obstet Gynecol 2003;102:317-318.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
27. Moran L, Teede H. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 2009;15:477-488.
28. Pirwany IR, Fleming R, Greer IA, Packard CJ, Sattar N. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters. Clin Endocrinol (Oxf) 2001; 54:447-453.
29. Pugeat M, Crave JC, Tourniaire J, Forest MG. Clinical utility of sex hormone-binding globulin measurement. Horm Res 1996;45:148-155.
30. Rajkhowa M, Neary RH, Kumpatla P, Game FL, Jones PW, Obhrai MS, Clayton RN. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:3389-3394.
31. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinas GA, Carmina E. Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. Hum Reprod 2009; 24:2286-2292.
32. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
33. Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004; 81:19-25.
34. Smith S, Pfeifer SM, Collins JA. Diagnosis and management of female infertility. JAMA 2003;290:1767-1770.
35. Strauss JF III. The synthesis and metabolism of steroid hormones. In: Strauss JF, Barbieri RL (eds). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management, 5th edn, Philadelphia, PA: Elsevier, 2004, 125-154.
36. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470-476.
37. Wactawski-Wende J, Schisterman EF, Hovey KM, Howards PP, Browne RW, Hediger M, Liu A, Trevisan M, for the BioCycle Study Group. BioCycle study: design of the longitudinal study of the oxidative stress and hormone variation during the menstrual cycle. Paediatr Perinat Epidemiol 2009;23:171-184.
38. Yilmaz M, Biri A, Bukan N, Karakoc A, Sancak B, Toruner F, Pasaoglu H. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome. Gynecol Endocrinol 2005; 20:258-263.
39. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F (eds). Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 1992, 377-384.